Yuejin Yang, Xiangdong Li, Guihao Chen, Ying Xian, Haitao Zhang, Yuan Wu, Yanmin Yang, Jianhua Wu, Chuntong Wang, Shenghu He, Zhong Wang, Yixin Wang, Zhifang Wang, Hui Liu, Xiping Wang, Minzhou Zhang, Jun Zhang, Jia Li, Tao An, Hao Guan, Lin Li, Meixia Shang, Chen Yao, Yaling Han, Boli Zhang, Runlin Gao, Eric D Peterson
IMPORTANCE: Tongxinluo, a traditional Chinese medicine compound, has shown promise in in vitro, animal, and small human studies for myocardial infarction, but has not been rigorously evaluated in large randomized clinical trials. OBJECTIVE: To investigate whether Tongxinluo could improve clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial was conducted among patients with STEMI within 24 hours of symptom onset from 124 hospitals in China...
October 24, 2023: JAMA